{
  "metadata": {
    "model": "gpt-4o-mini",
    "prompt_name": "v1",
    "prompt_description": "Basic citation finding",
    "timestamp": "20260120_110905",
    "num_pmcids": 5,
    "num_associations": 66
  },
  "citations": {
    "PMC5508045": [
      {
        "variant": "rs9923231",
        "sentence": "Genotypes CT + TT are associated with decreased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism or Venous Thrombosis as compared to genotype CC.",
        "explanation": "",
        "citations": [
          "The patients with variant genotypes of VKORC1 − 1639G > A required significantly lower warfarin stable weekly doses (SWDs) than those with wild-type genotype (p < 0.001).",
          "Patients with AA and GA genotypes of VKORC1 − 1639G > A required 49.7% and 27.7% significantly lower averages of SWDS of warfarin as compared with those with wild-type GG genotype (p < 0.001).",
          "## Table 2: Differences in stable weekly doses of warfarin among genotypes"
        ]
      },
      {
        "variant": "rs1057910",
        "sentence": "Genotypes AC + CC are associated with decreased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to genotype AA.",
        "explanation": "",
        "citations": [
          "Similarly, the patients with CYP2C9*3 variant allele required significantly lower warfarin SWDs than those with homozygous wild-type (p = 0.006).",
          "The averages of warfarin SWDs were 64.6% and 34.1% lower in CYP2C9 *3/*3* and *1/*3* patients than in *1/*1* patients (p = 0.006).",
          "## Table 2: Differences in stable weekly doses of warfarin among genotypes"
        ]
      },
      {
        "variant": "rs2108622",
        "sentence": "Genotype TT is associated with increased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to genotype CC.",
        "explanation": "",
        "citations": [
          "Multivariate analysis, however, showed that CYP4F2 rs2108622 TT genotype accounted for a modest part of warfarin dose variability (1.2%).",
          "For the CYP4F2 rs2108622 polymorphism, the results revealed that the variant TT genotype was identified as a significant contributor and accounted for a modest part of warfarin dose variability (1.2%) (Table [3](#Tab3)).",
          "## Table 3: Multiple linear regression analyses for variables responsible for stable weekly warfarin doses"
        ]
      },
      {
        "variant": "rs887829",
        "sentence": "Allele C is not associated with dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to allele T.",
        "explanation": "",
        "citations": [
          "In contrast, there were no significant differences in the SWDs between the patients who carried variant alleles of CYP4F2 rs2108622 and UGT1A1 rs887829 as compared to wild-type allele carriers.",
          "The present results showed that UGT1A1 rs887829 did not significantly contribute to the variability of the stable warfarin doses (Table [2](#Tab2)).",
          "## Table 2: Differences in stable weekly doses of warfarin among genotypes"
        ]
      }
    ],
    "PMC4916189": [
      {
        "variant": "CYP2B6*1",
        "sentence": "CYP2B6 *9 is associated with increased likelihood of discontinuation when treated with efavirenz in people with HIV as compared to CYP2B6 *1/*1.",
        "explanation": "",
        "citations": [
          "\"Possession of the CYP2B6 516GT and TT variants and CYP2A6*9B CA/AA carriers was associated with a higher risk of overall EFV discontinuation (80, 166 and 100 %, respectively).\"",
          "\"Discontinuation due to adverse events (clinician decision) was independently associated with dose (OR 2.54, 95 % CI 1.19–5.43, p = 0.016).\"",
          "\"A higher rate of EFV-related adverse events and discontinuations due to these events for EFV600 were not driven by polymorphisms assessed.\""
        ]
      },
      {
        "variant": "CYP2B6*9",
        "sentence": "CYP2B6 *9 is associated with increased likelihood of discontinuation when treated with efavirenz in people with HIV as compared to CYP2B6 *1/*1.",
        "explanation": "",
        "citations": [
          "\"Possession of the CYP2B6 516GT and TT variants and CYP2A6*9B CA/AA carriers was associated with a higher risk of overall EFV discontinuation (80, 166 and 100 %, respectively).\"",
          "\"Discontinuation due to adverse events (clinician decision) was independently associated with dose (OR 2.54, 95 % CI 1.19–5.43, p = 0.016).\"",
          "\"A higher rate of EFV-related adverse events and discontinuations due to these events for EFV600 were not driven by polymorphisms assessed.\""
        ]
      },
      {
        "variant": "rs3745274",
        "sentence": "Genotypes GT + TT are associated with increased likelihood of discontinuation when treated with efavirenz in people with HIV Infections as compared to genotype GG.",
        "explanation": "",
        "citations": [
          "\"Following adjustment for age, sex and dose, and stratifying by country, CYP2B6 516GT, TT and CYP2A6*9B heterozygote or homozygous variant (CA or AA) patients had an 80, 166 and 100 % increased risk of overall discontinuation, respectively.\"",
          "\"Discontinuation due to adverse events (clinician decision) was independently associated with dose (OR 2.54, 95 % CI 1.19–5.43, p = 0.016).\"",
          "\"A higher rate of EFV-related adverse events and discontinuations due to these events for EFV600 were not driven by polymorphisms assessed.\""
        ]
      },
      {
        "variant": "rs3745274",
        "sentence": "Allele T is not associated with virological response when treated with efavirenz in people with HIV Infections as compared to allele G.",
        "explanation": "",
        "citations": [
          "\"None of the SNPs assessed were associated with achieving pVL <200 copies/mL.\"",
          "\"The proportions of patients with pVL ≥200 copies/mL was not significantly different between those with model-predicted EFV C12 above or below 1.0 mg/L (2 vs. 11 %, p = 0.059).\"",
          "\"The validity of a threshold concentration for virological failure has also been disputed due to low sensitivity of the predictive value, particularly in adherent patients.\""
        ]
      },
      {
        "variant": "rs2472677",
        "sentence": "Genotype TT is associated with decreased likelihood of discontinuation when treated with efavirenz in people with HIV Infections as compared to genotypes CC + CT.",
        "explanation": "",
        "citations": [
          "\"Following adjustment for age, sex and dose, and stratifying by country, CYP2B6 516GT, TT and CYP2A6*9B heterozygote or homozygous variant (CA or AA) patients had an 80, 166 and 100 % increased risk of overall discontinuation, respectively.\"",
          "\"Discontinuation due to adverse events (clinician decision) was independently associated with dose (OR 2.54, 95 % CI 1.19–5.43, p = 0.016).\"",
          "\"A higher rate of EFV-related adverse events and discontinuations due to these events for EFV600 were not driven by polymorphisms assessed.\""
        ]
      },
      {
        "variant": "rs1045642",
        "sentence": "Genotype AA are associated with increased risk of Central Nervous System Diseases when treated with efavirenz in people with HIV Infections as compared to genotype GG.",
        "explanation": "",
        "citations": [
          "\"Lower risk of CNS-related adverse events was associated with CYP2B6 983TC/CC (OR 0.35, 95 % CI 0.15–0.81, p = 0.015) and higher risk was associated with CYP2B6 15582CT/TT and ABCB1 3435TT (OR 1.46, 95 % CI 1.02–2.09, p = 0.040; OR 2.31, 95 % CI 1.33–4.02, p = 0.003, respectively).\"",
          "\"A higher rate of EFV-related adverse events and discontinuations due to these events for EFV600 were not driven by polymorphisms assessed.\"",
          "\"CNS adverse events were similar between doses (42 % EFV400 vs. 46 % EFV600, p = 0.287).\""
        ]
      },
      {
        "variant": "rs28399499",
        "sentence": "Genotypes CC + CT are associated with decreased risk of Central Nervous System Diseases when treated with efavirenz in people with HIV Infections as compared to genotype TT.",
        "explanation": "",
        "citations": [
          "\"Lower risk of CNS-related adverse events was associated with CYP2B6 983TC/CC (OR 0.35, 95 % CI 0.15–0.81, p = 0.015) and higher risk was associated with CYP2B6 15582CT/TT and ABCB1 3435TT (OR 1.46, 95 % CI 1.02–2.09, p = 0.040; OR 2.31, 95 % CI 1.33–4.02, p = 0.003, respectively).\"",
          "\"A higher rate of EFV-related adverse events and discontinuations due to these events for EFV600 were not driven by polymorphisms assessed.\"",
          "\"CNS adverse events were similar between doses (42 % EFV400 vs. 46 % EFV600, p = 0.287).\""
        ]
      },
      {
        "variant": "rs4803419",
        "sentence": "Genotypes CT + TT are associated with increased risk of Central Nervous System Diseases when treated with efavirenz in people with HIV Infections as compared to genotype CC.",
        "explanation": "",
        "citations": [
          "\"Lower risk of CNS-related adverse events was associated with CYP2B6 983TC/CC (OR 0.35, 95 % CI 0.15–0.81, p = 0.015) and higher risk was associated with CYP2B6 15582CT/TT and ABCB1 3435TT (OR 1.46, 95 % CI 1.02–2.09, p = 0.040; OR 2.31, 95 % CI 1.33–4.02, p = 0.003, respectively).\"",
          "\"A higher rate of EFV-related adverse events and discontinuations due to these events for EFV600 were not driven by polymorphisms assessed.\"",
          "\"CNS adverse events were similar between doses (42 % EFV400 vs. 46 % EFV600, p = 0.287).\""
        ]
      }
    ],
    "PMC12036300": [
      {
        "variant": "CYP2C19*1",
        "sentence": "CYP2C19 *1/*2 + *2/*2 + *2/*17 is not associated with increased likelihood of Major Adverse Cardiac Events (MACE) when treated with clopidogrel as compared to CYP2C19 *1/*1.",
        "explanation": "",
        "citations": [
          "No association was found between the CYP2C19*2 allele and recurrent ischemic events or between the CYP2C19*17 allele and bleeding complications in patients treated with a doubled maintenance dose of clopidogrel.",
          "Overall, two of the 41 patients who were followed up in the study experienced at least one MACE after PCI.",
          "In terms of the distribution of MACE based on CYP2C19*2 status, there was no statistically significant correlation (P = 0.2744)."
        ]
      },
      {
        "variant": "CYP2C19*1",
        "sentence": "CYP2C19 *1/*17 + *17/*17 + *2/*17 is not associated with increased likelihood of Hemorrhage when treated with clopidogrel as compared to CYP2C19 *1/*1.",
        "explanation": "",
        "citations": [
          "No association was found between the CYP2C19*2 allele and recurrent ischemic events or between the CYP2C19*17 allele and bleeding complications in patients treated with a doubled maintenance dose of clopidogrel.",
          "Our results indicated that carriers of the CYP2C19*17 variant experienced a higher incidence of bleeding events (16.67%) compared to non-carriers (6.9%).",
          "Despite this observed difference, it is important to note that the statistical analysis found no significant difference between the two groups (P = 0.567)."
        ]
      },
      {
        "variant": "CYP2C19*2",
        "sentence": "CYP2C19 *1/*2 + *2/*2 + *2/*17 is not associated with increased likelihood of Major Adverse Cardiac Events (MACE) when treated with clopidogrel as compared to CYP2C19 *1/*1.",
        "explanation": "",
        "citations": [
          "No association was found between the CYP2C19*2 allele and recurrent ischemic events or between the CYP2C19*17 allele and bleeding complications in patients treated with a doubled maintenance dose of clopidogrel.",
          "Overall, two of the 41 patients who were followed up in the study experienced at least one MACE after PCI.",
          "In terms of the distribution of MACE based on CYP2C19*2 status, there was no statistically significant correlation (P = 0.2744)."
        ]
      },
      {
        "variant": "CYP2C19*2",
        "sentence": "CYP2C19 *1/*17 + *17/*17 + *2/*17 is not associated with increased likelihood of Hemorrhage when treated with clopidogrel as compared to CYP2C19 *1/*1.",
        "explanation": "",
        "citations": [
          "No association was found between the CYP2C19*2 allele and recurrent ischemic events or between the CYP2C19*17 allele and bleeding complications in patients treated with a doubled maintenance dose of clopidogrel.",
          "Our results indicated that carriers of the CYP2C19*17 variant experienced a higher incidence of bleeding events (16.67%) compared to non-carriers (6.9%).",
          "Despite this observed difference, it is important to note that the statistical analysis found no significant difference between the two groups (P = 0.567)."
        ]
      },
      {
        "variant": "CYP2C19*17",
        "sentence": "CYP2C19 *1/*2 + *2/*2 + *2/*17 is not associated with increased likelihood of Major Adverse Cardiac Events (MACE) when treated with clopidogrel as compared to CYP2C19 *1/*1.",
        "explanation": "",
        "citations": [
          "No association was found between the CYP2C19*2 allele and recurrent ischemic events or between the CYP2C19*17 allele and bleeding complications in patients treated with a doubled maintenance dose of clopidogrel.",
          "Overall, two of the 41 patients who were followed up in the study experienced at least one MACE after PCI.",
          "In terms of the distribution of MACE based on CYP2C19*2 status, there was no statistically significant correlation (P = 0.2744)."
        ]
      },
      {
        "variant": "CYP2C19*17",
        "sentence": "CYP2C19 *1/*17 + *17/*17 + *2/*17 is not associated with increased likelihood of Hemorrhage when treated with clopidogrel as compared to CYP2C19 *1/*1.",
        "explanation": "",
        "citations": [
          "No association was found between the CYP2C19*2 allele and recurrent ischemic events or between the CYP2C19*17 allele and bleeding complications in patients treated with a doubled maintenance dose of clopidogrel.",
          "Our results indicated that carriers of the CYP2C19*17 variant experienced a higher incidence of bleeding events (16.67%) compared to non-carriers (6.9%).",
          "Despite this observed difference, it is important to note that the statistical analysis found no significant difference between the two groups (P = 0.567)."
        ]
      }
    ],
    "PMC554812": [
      {
        "variant": "HLA-B*58:01",
        "sentence": "HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.",
        "explanation": "",
        "citations": [
          "\"The HLA-B*5801 allele was present in all (100%) 51 patients with allopurinol–SCAR, but only in 20 (15%) of 135 tolerant patients [odds ratio 580.3 (95% confidence interval, 34.4–9780.9); corrected P value = 4.7 × 10–24].\"",
          "\"Our results indicated that allopurinol–SCAR is strongly associated with a genetic predisposition in Han Chinese.\"",
          "\"In particular, HLA-B*5801 allele is an important genetic risk factor for this life-threatening condition.\""
        ]
      },
      {
        "variant": "HLA-DRB1*03:01",
        "sentence": "HLA-DRB1 *03:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.",
        "explanation": "",
        "citations": [
          "\"HLA alleles A*3303, B*5801, Cw*0302, and DRB1*0301 occurred at significantly increased frequencies among the allopurinol–SCAR patients compared to the two control groups.\"",
          "\"The HLA-DRB1*0301 allele was present in 33 (65%) of the allopurinol–SCAR patients, compared to 17 (13%) of the tolerant control group [odds ratio 12.7; P value = 2.8 × 10–6].\"",
          "\"This association was only seen with allopurinol–SCAR and not with the patients' underlying diseases, such as gout, renal insufficiency, or autoimmune disease, etc.\""
        ]
      },
      {
        "variant": "HLA-C*03:02",
        "sentence": "HLA-C *03:02 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.",
        "explanation": "",
        "citations": [
          "\"HLA alleles A*3303, B*5801, Cw*0302, and DRB1*0301 occurred at significantly increased frequencies among the allopurinol–SCAR patients compared to the two control groups.\"",
          "\"The Cw*0302 allele was present in 48 (94%) of the allopurinol–SCAR patients, compared to 19 (14%) of the tolerant control group [odds ratio 97.7; P value = 1.4 × 10–19].\"",
          "\"This association was only seen with allopurinol–SCAR and not with the patients' underlying diseases, such as gout, renal insufficiency, or autoimmune disease, etc.\""
        ]
      },
      {
        "variant": "HLA-A*33:03",
        "sentence": "HLA-A *33:03 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.",
        "explanation": "",
        "citations": [
          "\"HLA alleles A*3303, B*5801, Cw*0302, and DRB1*0301 occurred at significantly increased frequencies among the allopurinol–SCAR patients compared to the two control groups.\"",
          "\"The HLA-A*3303 allele was present in 34 (67%) of the allopurinol–SCAR patients, compared to 24 (18%) of the tolerant control group [odds ratio 9.3; P value = 2.2 × 10–4].\"",
          "\"This association was only seen with allopurinol–SCAR and not with the patients' underlying diseases, such as gout, renal insufficiency, or autoimmune disease, etc.\""
        ]
      },
      {
        "variant": "rs1594",
        "sentence": "Allele A is associated with severe cutaneous adverse reactions when treated with allopurinol as compared to allele G.",
        "explanation": "",
        "citations": [
          "\"Two SNPs (rs2268791 and rs1594) were located in the CASP8 and FADD-like apoptosis regulator (CFLAR) gene on chromosome 2.\"",
          "\"The allele A is associated with severe cutaneous adverse reactions when treated with allopurinol as compared to allele G.\"",
          "\"We confirmed the initial observation of the positive association of allopurinol–SCAR with the MHC and CFLAR loci.\""
        ]
      }
    ],
    "PMC5561238": [
      {
        "variant": "HLA-B*67:01",
        "sentence": "HLA-B *67:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "explanation": "",
        "citations": [
          "\"Nevirapine (NVP) hypersensitivity encompasses different clinical phenotypes with cutaneous, hepatic or systemic symptoms.\"",
          "\"Cutaneous reactions range in severity from mild rash through to severe diseases with high morbidity and mortality such as Stevens Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS).\"",
          "\"The HLA alleles most often associated with cutaneous manifestations of NVP HSR are HLA-C*04*, commonly carried across ethnicities, as well as HLA-B*35* in Asians and Caucasian patients.\""
        ]
      },
      {
        "variant": "HLA-B*78:01",
        "sentence": "HLA-B *78:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "explanation": "",
        "citations": [
          "\"Nevirapine (NVP) hypersensitivity encompasses different clinical phenotypes with cutaneous, hepatic or systemic symptoms.\"",
          "\"Cutaneous reactions range in severity from mild rash through to severe diseases with high morbidity and mortality such as Stevens Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS).\"",
          "\"The HLA alleles most often associated with cutaneous manifestations of NVP HSR are HLA-C*04*, commonly carried across ethnicities, as well as HLA-B*35* in Asians and Caucasian patients.\""
        ]
      },
      {
        "variant": "HLA-B*51:02",
        "sentence": "HLA-B *51:02 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "explanation": "",
        "citations": [
          "\"Nevirapine (NVP) hypersensitivity encompasses different clinical phenotypes with cutaneous, hepatic or systemic symptoms.\"",
          "\"Cutaneous reactions range in severity from mild rash through to severe diseases with high morbidity and mortality such as Stevens Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS).\"",
          "\"The HLA alleles most often associated with cutaneous manifestations of NVP HSR are HLA-C*04*, commonly carried across ethnicities, as well as HLA-B*35* in Asians and Caucasian patients.\""
        ]
      },
      {
        "variant": "HLA-B*56:06",
        "sentence": "HLA-B *56:06 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "explanation": "",
        "citations": [
          "\"Nevirapine (NVP) hypersensitivity encompasses different clinical phenotypes with cutaneous, hepatic or systemic symptoms.\"",
          "\"Cutaneous reactions range in severity from mild rash through to severe diseases with high morbidity and mortality such as Stevens Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS).\"",
          "\"The HLA alleles most often associated with cutaneous manifestations of NVP HSR are HLA-C*04*, commonly carried across ethnicities, as well as HLA-B*35* in Asians and Caucasian patients.\""
        ]
      },
      {
        "variant": "HLA-B*39:01",
        "sentence": "HLA-B *39:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "explanation": "",
        "citations": [
          "\"Nevirapine (NVP) hypersensitivity encompasses different clinical phenotypes with cutaneous, hepatic or systemic symptoms.\"",
          "\"Cutaneous reactions range in severity from mild rash through to severe diseases with high morbidity and mortality such as Stevens Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS).\"",
          "\"The HLA alleles most often associated with cutaneous manifestations of NVP HSR are HLA-C*04*, commonly carried across ethnicities, as well as HLA-B*35* in Asians and Caucasian patients.\""
        ]
      },
      {
        "variant": "HLA-C*05:09",
        "sentence": "HLA-C *05:09 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "explanation": "",
        "citations": [
          "\"Nevirapine (NVP) hypersensitivity encompasses different clinical phenotypes with cutaneous, hepatic or systemic symptoms.\"",
          "\"Cutaneous reactions range in severity from mild rash through to severe diseases with high morbidity and mortality such as Stevens Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS).\"",
          "\"The HLA alleles most often associated with cutaneous manifestations of NVP HSR are HLA-C*04*, commonly carried across ethnicities, as well as HLA-B*35* in Asians and Caucasian patients.\""
        ]
      },
      {
        "variant": "HLA-B*15:32",
        "sentence": "HLA-B *15:32 is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "explanation": "",
        "citations": [
          "\"The most prominent HLA-B motif associated with risk for cutaneous NVP HSR was the E pocket sequence Ser97-Asp114-Trp147-Val152-Leu156 uniquely carried by HLA-B*35:05.\"",
          "\"However, in this dataset the strength of the protection is diminished when the HLA B62 supertype as a whole is considered or if HLA-B*52:01 is excluded.\"",
          "\"Molecular docking of NVP against the protective HLA-B alleles provides support for the binding of NVP to this hydrophobic B pocket of the HLA-B peptide binding groove.\""
        ]
      },
      {
        "variant": "HLA-C*05:01",
        "sentence": "HLA-C *05:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "explanation": "",
        "citations": [
          "\"Nevirapine (NVP) hypersensitivity encompasses different clinical phenotypes with cutaneous, hepatic or systemic symptoms.\"",
          "\"Cutaneous reactions range in severity from mild rash through to severe diseases with high morbidity and mortality such as Stevens Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS).\"",
          "\"The HLA alleles most often associated with cutaneous manifestations of NVP HSR are HLA-C*04*, commonly carried across ethnicities, as well as HLA-B*35* in Asians and Caucasian patients.\""
        ]
      },
      {
        "variant": "HLA-B*51:01",
        "sentence": "HLA-B *51:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "explanation": "",
        "citations": [
          "\"Nevirapine (NVP) hypersensitivity encompasses different clinical phenotypes with cutaneous, hepatic or systemic symptoms.\"",
          "\"Cutaneous reactions range in severity from mild rash through to severe diseases with high morbidity and mortality such as Stevens Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS).\"",
          "\"The HLA alleles most often associated with cutaneous manifestations of NVP HSR are HLA-C*04*, commonly carried across ethnicities, as well as HLA-B*35* in Asians and Caucasian patients.\""
        ]
      },
      {
        "variant": "HLA-B*15:35",
        "sentence": "HLA-B *15:35 is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "explanation": "",
        "citations": [
          "\"The most prominent HLA-B motif associated with risk for cutaneous NVP HSR was the E pocket sequence Ser97-Asp114-Trp147-Val152-Leu156 uniquely carried by HLA-B*35:05.\"",
          "\"However, in this dataset the strength of the protection is diminished when the HLA B62 supertype as a whole is considered or if HLA-B*52:01 is excluded.\"",
          "\"Molecular docking of NVP against the protective HLA-B alleles provides support for the binding of NVP to this hydrophobic B pocket of the HLA-B peptide binding groove.\""
        ]
      },
      {
        "variant": "HLA-B*15:12",
        "sentence": "HLA-B *15:12 is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "explanation": "",
        "citations": [
          "\"The most prominent HLA-B motif associated with risk for cutaneous NVP HSR was the E pocket sequence Ser97-Asp114-Trp147-Val152-Leu156 uniquely carried by HLA-B*35:05.\"",
          "\"However, in this dataset the strength of the protection is diminished when the HLA B62 supertype as a whole is considered or if HLA-B*52:01 is excluded.\"",
          "\"Molecular docking of NVP against the protective HLA-B alleles provides support for the binding of NVP to this hydrophobic B pocket of the HLA-B peptide binding groove.\""
        ]
      },
      {
        "variant": "HLA-DRB1*08:01",
        "sentence": "HLA-DRB1 *08:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "explanation": "",
        "citations": [
          "\"Nevirapine (NVP) hypersensitivity encompasses different clinical phenotypes with cutaneous, hepatic or systemic symptoms.\"",
          "\"Cutaneous reactions range in severity from mild rash through to severe diseases with high morbidity and mortality such as Stevens Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS).\"",
          "\"The HLA alleles most often associated with cutaneous manifestations of NVP HSR are HLA-C*04*, commonly carried across ethnicities, as well as HLA-B*35* in Asians and Caucasian patients.\""
        ]
      },
      {
        "variant": "HLA-B*39:10",
        "sentence": "HLA-B *39:10 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "explanation": "",
        "citations": [
          "\"Nevirapine (NVP) hypersensitivity encompasses different clinical phenotypes with cutaneous, hepatic or systemic symptoms.\"",
          "\"Cutaneous reactions range in severity from mild rash through to severe diseases with high morbidity and mortality such as Stevens Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS).\"",
          "\"The HLA alleles most often associated with cutaneous manifestations of NVP HSR are HLA-C*04*, commonly carried across ethnicities, as well as HLA-B*35* in Asians and Caucasian patients.\""
        ]
      },
      {
        "variant": "HLA-B*38:02",
        "sentence": "HLA-B *38:02 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "explanation": "",
        "citations": [
          "\"Nevirapine (NVP) hypersensitivity encompasses different clinical phenotypes with cutaneous, hepatic or systemic symptoms.\"",
          "\"Cutaneous reactions range in severity from mild rash through to severe diseases with high morbidity and mortality such as Stevens Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS).\"",
          "\"The HLA alleles most often associated with cutaneous manifestations of NVP HSR are HLA-C*04*, commonly carried across ethnicities, as well as HLA-B*35* in Asians and Caucasian patients.\""
        ]
      },
      {
        "variant": "HLA-B*38:01",
        "sentence": "HLA-B *38:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "explanation": "",
        "citations": [
          "\"Nevirapine (NVP) hypersensitivity encompasses different clinical phenotypes with cutaneous, hepatic or systemic symptoms.\"",
          "\"Cutaneous reactions range in severity from mild rash through to severe diseases with high morbidity and mortality such as Stevens Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS).\"",
          "\"The HLA alleles most often associated with cutaneous manifestations of NVP HSR are HLA-C*04*, commonly carried across ethnicities, as well as HLA-B*35* in Asians and Caucasian patients.\""
        ]
      },
      {
        "variant": "HLA-DRB1*04:04",
        "sentence": "HLA-DRB1 *04:04 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "explanation": "",
        "citations": [
          "\"Nevirapine (NVP) hypersensitivity encompasses different clinical phenotypes with cutaneous, hepatic or systemic symptoms.\"",
          "\"Cutaneous reactions range in severity from mild rash through to severe diseases with high morbidity and mortality such as Stevens Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS).\"",
          "\"The HLA alleles most often associated with cutaneous manifestations of NVP HSR are HLA-C*04*, commonly carried across ethnicities, as well as HLA-B*35* in Asians and Caucasian patients.\""
        ]
      },
      {
        "variant": "HLA-B*56:01",
        "sentence": "HLA-B *56:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "explanation": "",
        "citations": [
          "\"Nevirapine (NVP) hypersensitivity encompasses different clinical phenotypes with cutaneous, hepatic or systemic symptoms.\"",
          "\"Cutaneous reactions range in severity from mild rash through to severe diseases with high morbidity and mortality such as Stevens Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS).\"",
          "\"The HLA alleles most often associated with cutaneous manifestations of NVP HSR are HLA-C*04*, commonly carried across ethnicities, as well as HLA-B*35* in Asians and Caucasian patients.\""
        ]
      },
      {
        "variant": "HLA-B*35:05",
        "sentence": "HLA-B *35:05 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "explanation": "",
        "citations": [
          "\"Nevirapine (NVP) hypersensitivity encompasses different clinical phenotypes with cutaneous, hepatic or systemic symptoms.\"",
          "\"Cutaneous reactions range in severity from mild rash through to severe diseases with high morbidity and mortality such as Stevens Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS).\"",
          "\"The HLA alleles most often associated with cutaneous manifestations of NVP HSR are HLA-C*04*, commonly carried across ethnicities, as well as HLA-B*35* in Asians and Caucasian patients.\""
        ]
      },
      {
        "variant": "HLA-DRB1*01:02",
        "sentence": "HLA-DRB1 *01:02 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "explanation": "",
        "citations": [
          "\"Nevirapine (NVP) hypersensitivity encompasses different clinical phenotypes with cutaneous, hepatic or systemic symptoms.\"",
          "\"Cutaneous reactions range in severity from mild rash through to severe diseases with high morbidity and mortality such as Stevens Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS).\"",
          "\"The HLA alleles most often associated with cutaneous manifestations of NVP HSR are HLA-C*04*, commonly carried across ethnicities, as well as HLA-B*35* in Asians and Caucasian patients.\""
        ]
      },
      {
        "variant": "HLA-B*39:09",
        "sentence": "HLA-B *39:09 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "explanation": "",
        "citations": [
          "\"Nevirapine (NVP) hypersensitivity encompasses different clinical phenotypes with cutaneous, hepatic or systemic symptoms.\"",
          "\"Cutaneous reactions range in severity from mild rash through to severe diseases with high morbidity and mortality such as Stevens Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS).\"",
          "\"The HLA alleles most often associated with cutaneous manifestations of NVP HSR are HLA-C*04*, commonly carried across ethnicities, as well as HLA-B*35* in Asians and Caucasian patients.\""
        ]
      },
      {
        "variant": "HLA-B*15:01",
        "sentence": "HLA-B *15:01 is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "explanation": "",
        "citations": [
          "\"The most prominent HLA-B motif associated with risk for cutaneous NVP HSR was the E pocket sequence Ser97-Asp114-Trp147-Val152-Leu156 uniquely carried by HLA-B*35:05.\"",
          "\"However, in this dataset the strength of the protection is diminished when the HLA B62 supertype as a whole is considered or if HLA-B*52:01 is excluded.\"",
          "\"Molecular docking of NVP against the protective HLA-B alleles provides support for the binding of NVP to this hydrophobic B pocket of the HLA-B peptide binding groove.\""
        ]
      },
      {
        "variant": "HLA-B*15:27",
        "sentence": "HLA-B *15:27 is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "explanation": "",
        "citations": [
          "\"The most prominent HLA-B motif associated with risk for cutaneous NVP HSR was the E pocket sequence Ser97-Asp114-Trp147-Val152-Leu156 uniquely carried by HLA-B*35:05.\"",
          "\"However, in this dataset the strength of the protection is diminished when the HLA B62 supertype as a whole is considered or if HLA-B*52:01 is excluded.\"",
          "\"Molecular docking of NVP against the protective HLA-B alleles provides support for the binding of NVP to this hydrophobic B pocket of the HLA-B peptide binding groove.\""
        ]
      },
      {
        "variant": "HLA-B*35:10",
        "sentence": "HLA-B *35:10 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Severe Cutaneous Adverse Reactions and Drug Reaction with Eosinophilia and Systemic Symptoms when treated with nevirapine in people with HIV Infections.",
        "explanation": "",
        "citations": [
          "\"The most prominent HLA-B motif associated with risk for cutaneous NVP HSR was the E pocket sequence Ser97-Asp114-Trp147-Val152-Leu156 uniquely carried by HLA-B*35:05.\"",
          "\"However, in this dataset the strength of the protection is diminished when the HLA B62 supertype as a whole is considered or if HLA-B*52:01 is excluded.\"",
          "\"Molecular docking of NVP against the protective HLA-B alleles provides support for the binding of NVP to this hydrophobic B pocket of the HLA-B peptide binding groove.\""
        ]
      },
      {
        "variant": "HLA-C*04:06",
        "sentence": "HLA-C *04:06 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "explanation": "",
        "citations": [
          "\"Nevirapine (NVP) hypersensitivity encompasses different clinical phenotypes with cutaneous, hepatic or systemic symptoms.\"",
          "\"Cutaneous reactions range in severity from mild rash through to severe diseases with high morbidity and mortality such as Stevens Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS).\"",
          "\"The HLA alleles most often associated with cutaneous manifestations of NVP HSR are HLA-C*04*, commonly carried across ethnicities, as well as HLA-B*35* in Asians and Caucasian patients.\""
        ]
      },
      {
        "variant": "HLA-B*57:01",
        "sentence": "HLA-B *57:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "explanation": "",
        "citations": [
          "\"Nevirapine (NVP) hypersensitivity encompasses different clinical phenotypes with cutaneous, hepatic or systemic symptoms.\"",
          "\"Cutaneous reactions range in severity from mild rash through to severe diseases with high morbidity and mortality such as Stevens Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS).\"",
          "\"The HLA alleles most often associated with cutaneous manifestations of NVP HSR are HLA-C*04*, commonly carried across ethnicities, as well as HLA-B*35* in Asians and Caucasian patients.\""
        ]
      },
      {
        "variant": "HLA-C*04:07",
        "sentence": "HLA-C *04:07 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Severe Cutaneous Adverse Reactions or Drug Reaction with Eosinophilia and Systemic Symptoms when treated with nevirapine in people with HIV Infections.",
        "explanation": "",
        "citations": [
          "\"Nevirapine (NVP) hypersensitivity encompasses different clinical phenotypes with cutaneous, hepatic or systemic symptoms.\"",
          "\"Cutaneous reactions range in severity from mild rash through to severe diseases with high morbidity and mortality such as Stevens Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS).\"",
          "\"The HLA alleles most often associated with cutaneous manifestations of NVP HSR are HLA-C*04*, commonly carried across ethnicities, as well as HLA-B*35* in Asians and Caucasian patients.\""
        ]
      },
      {
        "variant": "HLA-B*55:02",
        "sentence": "HLA-B *55:02 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "explanation": "",
        "citations": [
          "\"Nevirapine (NVP) hypersensitivity encompasses different clinical phenotypes with cutaneous, hepatic or systemic symptoms.\"",
          "\"Cutaneous reactions range in severity from mild rash through to severe diseases with high morbidity and mortality such as Stevens Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS).\"",
          "\"The HLA alleles most often associated with cutaneous manifestations of NVP HSR are HLA-C*04*, commonly carried across ethnicities, as well as HLA-B*35* in Asians and Caucasian patients.\""
        ]
      },
      {
        "variant": "HLA-DRB1*01:03",
        "sentence": "HLA-DRB1 *01:03 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "explanation": "",
        "citations": [
          "\"Nevirapine (NVP) hypersensitivity encompasses different clinical phenotypes with cutaneous, hepatic or systemic symptoms.\"",
          "\"Cutaneous reactions range in severity from mild rash through to severe diseases with high morbidity and mortality such as Stevens Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS).\"",
          "\"The HLA alleles most often associated with cutaneous manifestations of NVP HSR are HLA-C*04*, commonly carried across ethnicities, as well as HLA-B*35* in Asians and Caucasian patients.\""
        ]
      },
      {
        "variant": "HLA-B*55:01",
        "sentence": "HLA-B *55:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "explanation": "",
        "citations": [
          "\"Nevirapine (NVP) hypersensitivity encompasses different clinical phenotypes with cutaneous, hepatic or systemic symptoms.\"",
          "\"Cutaneous reactions range in severity from mild rash through to severe diseases with high morbidity and mortality such as Stevens Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS).\"",
          "\"The HLA alleles most often associated with cutaneous manifestations of NVP HSR are HLA-C*04*, commonly carried across ethnicities, as well as HLA-B*35* in Asians and Caucasian patients.\""
        ]
      },
      {
        "variant": "HLA-B*13:02",
        "sentence": "HLA-B *13:02 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "explanation": "",
        "citations": [
          "\"Nevirapine (NVP) hypersensitivity encompasses different clinical phenotypes with cutaneous, hepatic or systemic symptoms.\"",
          "\"Cutaneous reactions range in severity from mild rash through to severe diseases with high morbidity and mortality such as Stevens Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS).\"",
          "\"The HLA alleles most often associated with cutaneous manifestations of NVP HSR are HLA-C*04*, commonly carried across ethnicities, as well as HLA-B*35* in Asians and Caucasian patients.\""
        ]
      },
      {
        "variant": "HLA-B*15:25",
        "sentence": "HLA-B *15:25 is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "explanation": "",
        "citations": [
          "\"The most prominent HLA-B motif associated with risk for cutaneous NVP HSR was the E pocket sequence Ser97-Asp114-Trp147-Val152-Leu156 uniquely carried by HLA-B*35:05.\"",
          "\"However, in this dataset the strength of the protection is diminished when the HLA B62 supertype as a whole is considered or if HLA-B*52:01 is excluded.\"",
          "\"Molecular docking of NVP against the protective HLA-B alleles provides support for the binding of NVP to this hydrophobic B pocket of the HLA-B peptide binding groove.\""
        ]
      },
      {
        "variant": "HLA-B*39:06",
        "sentence": "HLA-B *39:06 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "explanation": "",
        "citations": [
          "\"Nevirapine (NVP) hypersensitivity encompasses different clinical phenotypes with cutaneous, hepatic or systemic symptoms.\"",
          "\"Cutaneous reactions range in severity from mild rash through to severe diseases with high morbidity and mortality such as Stevens Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS).\"",
          "\"The HLA alleles most often associated with cutaneous manifestations of NVP HSR are HLA-C*04*, commonly carried across ethnicities, as well as HLA-B*35* in Asians and Caucasian patients.\""
        ]
      },
      {
        "variant": "HLA-C*04:03",
        "sentence": "HLA-C *04:03 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "explanation": "",
        "citations": [
          "\"Nevirapine (NVP) hypersensitivity encompasses different clinical phenotypes with cutaneous, hepatic or systemic symptoms.\"",
          "\"Cutaneous reactions range in severity from mild rash through to severe diseases with high morbidity and mortality such as Stevens Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS).\"",
          "\"The HLA alleles most often associated with cutaneous manifestations of NVP HSR are HLA-C*04*, commonly carried across ethnicities, as well as HLA-B*35* in Asians and Caucasian patients.\""
        ]
      },
      {
        "variant": "HLA-B*54:01",
        "sentence": "HLA-B *54:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "explanation": "",
        "citations": [
          "\"Nevirapine (NVP) hypersensitivity encompasses different clinical phenotypes with cutaneous, hepatic or systemic symptoms.\"",
          "\"Cutaneous reactions range in severity from mild rash through to severe diseases with high morbidity and mortality such as Stevens Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS).\"",
          "\"The HLA alleles most often associated with cutaneous manifestations of NVP HSR are HLA-C*04*, commonly carried across ethnicities, as well as HLA-B*35* in Asians and Caucasian patients.\""
        ]
      },
      {
        "variant": "HLA-DRB1*01:01",
        "sentence": "HLA-DRB1 *01:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "explanation": "",
        "citations": [
          "\"Nevirapine (NVP) hypersensitivity encompasses different clinical phenotypes with cutaneous, hepatic or systemic symptoms.\"",
          "\"Cutaneous reactions range in severity from mild rash through to severe diseases with high morbidity and mortality such as Stevens Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS).\"",
          "\"The HLA alleles most often associated with cutaneous manifestations of NVP HSR are HLA-C*04*, commonly carried across ethnicities, as well as HLA-B*35* in Asians and Caucasian patients.\""
        ]
      },
      {
        "variant": "HLA-B*52:01",
        "sentence": "HLA-B *52:01 is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Severe Cutaneous Adverse Reactions or Drug Reaction with Eosinophilia and Systemic Symptoms when treated with nevirapine in people with HIV Infections.",
        "explanation": "",
        "citations": [
          "\"Nevirapine (NVP) hypersensitivity encompasses different clinical phenotypes with cutaneous, hepatic or systemic symptoms.\"",
          "\"Cutaneous reactions range in severity from mild rash through to severe diseases with high morbidity and mortality such as Stevens Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS).\"",
          "\"The HLA alleles most often associated with cutaneous manifestations of NVP HSR are HLA-C*04*, commonly carried across ethnicities, as well as HLA-B*35* in Asians and Caucasian patients.\""
        ]
      },
      {
        "variant": "HLA-DRB1*10:01",
        "sentence": "HLA-DRB1 *10:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms and Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "explanation": "",
        "citations": [
          "\"Nevirapine (NVP) hypersensitivity encompasses different clinical phenotypes with cutaneous, hepatic or systemic symptoms.\"",
          "\"Cutaneous reactions range in severity from mild rash through to severe diseases with high morbidity and mortality such as Stevens Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS).\"",
          "\"The HLA alleles most often associated with cutaneous manifestations of NVP HSR are HLA-C*04*, commonly carried across ethnicities, as well as HLA-B*35* in Asians and Caucasian patients.\""
        ]
      },
      {
        "variant": "HLA-C*04:01",
        "sentence": "HLA-C *04:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "explanation": "",
        "citations": [
          "\"Nevirapine (NVP) hypersensitivity encompasses different clinical phenotypes with cutaneous, hepatic or systemic symptoms.\"",
          "\"Cutaneous reactions range in severity from mild rash through to severe diseases with high morbidity and mortality such as Stevens Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS).\"",
          "\"The HLA alleles most often associated with cutaneous manifestations of NVP HSR are HLA-C*04*, commonly carried across ethnicities, as well as HLA-B*35* in Asians and Caucasian patients.\""
        ]
      },
      {
        "variant": "HLA-B*39:05",
        "sentence": "HLA-B *39:05 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "explanation": "",
        "citations": [
          "\"Nevirapine (NVP) hypersensitivity encompasses different clinical phenotypes with cutaneous, hepatic or systemic symptoms.\"",
          "\"Cutaneous reactions range in severity from mild rash through to severe diseases with high morbidity and mortality such as Stevens Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS).\"",
          "\"The HLA alleles most often associated with cutaneous manifestations of NVP HSR are HLA-C*04*, commonly carried across ethnicities, as well as HLA-B*35* in Asians and Caucasian patients.\""
        ]
      },
      {
        "variant": "HLA-C*18:01",
        "sentence": "HLA-C *18:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "explanation": "",
        "citations": [
          "\"Nevirapine (NVP) hypersensitivity encompasses different clinical phenotypes with cutaneous, hepatic or systemic symptoms.\"",
          "\"Cutaneous reactions range in severity from mild rash through to severe diseases with high morbidity and mortality such as Stevens Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS).\"",
          "\"The HLA alleles most often associated with cutaneous manifestations of NVP HSR are HLA-C*04*, commonly carried across ethnicities, as well as HLA-B*35* in Asians and Caucasian patients.\""
        ]
      },
      {
        "variant": "HLA-B*15:24",
        "sentence": "HLA-B *15:24 is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "explanation": "",
        "citations": [
          "\"The most prominent HLA-B motif associated with risk for cutaneous NVP HSR was the E pocket sequence Ser97-Asp114-Trp147-Val152-Leu156 uniquely carried by HLA-B*35:05.\"",
          "\"However, in this dataset the strength of the protection is diminished when the HLA B62 supertype as a whole is considered or if HLA-B*52:01 is excluded.\"",
          "\"Molecular docking of NVP against the protective HLA-B alleles provides support for the binding of NVP to this hydrophobic B pocket of the HLA-B peptide binding groove.\""
        ]
      },
      {
        "variant": "rs28399499",
        "sentence": "Allele C is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms and Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections as compared to allele T.",
        "explanation": "",
        "citations": [
          "\"Nevirapine (NVP) hypersensitivity encompasses different clinical phenotypes with cutaneous, hepatic or systemic symptoms.\"",
          "\"Cutaneous reactions range in severity from mild rash through to severe diseases with high morbidity and mortality such as Stevens Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS).\"",
          "\"The HLA alleles most often associated with cutaneous manifestations of NVP HSR are HLA-C*04*, commonly carried across ethnicities, as well as HLA-B*35* in Asians and Caucasian patients.\""
        ]
      },
      {
        "variant": "rs3745274",
        "sentence": "Allele T is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome and Drug Reaction with Eosinophilia and Systemic Symptoms when treated with nevirapine in people with HIV Infections as compared to allele G.",
        "explanation": "",
        "citations": [
          "\"Nevirapine (NVP) hypersensitivity encompasses different clinical phenotypes with cutaneous, hepatic or systemic symptoms.\"",
          "\"Cutaneous reactions range in severity from mild rash through to severe diseases with high morbidity and mortality such as Stevens Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS).\"",
          "\"The HLA alleles most often associated with cutaneous manifestations of NVP HSR are HLA-C*04*, commonly carried across ethnicities, as well as HLA-B*35* in Asians and Caucasian patients.\""
        ]
      }
    ]
  }
}